Insurance Bureau issued the "Announcement on the Results of the Negotiations for the Su Yansu Xutonghuai Public Medical Institutions' Medical Consumables Alliance to Bring Volume Renewal and Expansion", showing:>
Diagnosis and treatment of necrotizing skin and soft tissue infections, a list of 2020 SIS guidelines!
Time of Update: 2021-03-23
[1B] ➤For rapidly progressive infections or severe infections caused by toxin-producing organisms, if the pathogen is sensitive to protein synthesis inhibitors clindamycin or linezolid, combination therapy should be considered.
2020 SIS Management Guidelines Update for Complex Skin and Soft Tissue Infections
Time of Update: 2021-03-23
[2C] Adjuvant antibiotic treatment ➤ After incision and drainage of a simple abscess, it is recommended to use trimethoprim-sulfamethoxazole (TMP-SMZ) or clindamycin for adjuvant antibiotic therapy for 7-10 days.
Pioneering pharmaceutical proclosamine treatment of severe new crown patients clinical trial death risk reduced by 92%
Time of Update: 2021-03-22
Hospital stay shortened by 9 days544px;white-space:normal;background-color:#FFFFFF;box-sizing:border-box !important;'> 544px;text-align:justify;background-color:#FFFFFF;box-sizing:border-box !important;overflow-wrap:break-word !important;'> Prokalamide treatment group (N=294) Placebo control group (N=296) Number of people percentage Number of people percentage mortality rate 11 3.
Eno and Biochemistry signed an agreement on the joint listing of Osteoarthritis treatment agent SI-613 in Korea
Time of Update: 2021-03-07
(Headquarters: Tokyo, President: Mito Jian, "Biochemistry") recently announced that the two companies have signed a joint listing agreement in South Korea on the biochemical pioneer osteoarthritis treatment SI-613 (bichlorofenate combined with sodium hyalurogenic acid).
Capillary Coating for Protein Separation Based on Si-O and Si-C Covalent Bond Formation
Time of Update: 2021-03-05
Coating the capillary with different materials is used to reduce the adsorption.
Health and Wellness Commission: 30 new crown confirmed 92 cases of local 73 cases
Time of Update: 2021-02-02
(Shanghai 7 cases, Liaoning 3 cases, Guangdong 3 cases, Fujian 2 cases, Shaanxi 2 cases, Jiangsu 1 case, Sichuan 1 case), 73 local cases (63 cases in Jilin, 9 cases in Heilongjiang, 1 case in Hebei); 135 new cases were cured and discharged from
CD19 CAR-T Cell Therapy! Gilead Yescarta Treatment Recurrence/Difficult Inert Non-Hodgkin's Lymphoma (iNHL): Total remission rate of 92%!
Time of Update: 2020-12-18
data released at the ASH Annual Meeting showed that after receiving Yescarta's single infusion treatment, the medium follow-up was 17.5 months: 92% of the 104 patients with assessable efficacy were in remission (ORR-92%) and 76% were fully relieved (CR-76%).
Cashew phenol-derived P and Si-based prebiobodies are used in flame retardant PU coatings
Time of Update: 2020-11-19
A new study has proposed an attempt to develop flame retardant coatings from cashew phenol as a starting material chinese .
Si Group sells industrial resins to Ask Chemicals
Time of Update: 2020-11-07
The business provides ASK with the know-how and know-how of its industrial resin business, while recalcuiting our focus on performance additives.
in Meshadon: complete 2 years of Keytruda treatment of patients with a 3-year survival rate of 92%!
Time of Update: 2020-11-02
compared to pure chemotherapy (n-63): (1) objective remission rate (ORR:58% vs 33%) was significantly increased, and medium remission duration (DOR) was extended by more than one year (36) .3 months) vs 22.8 months) ;(2) No progression lifetime
Total mitigation rate of 92%! FDA grants Gilead CD47 single anti-magrolimab breakthrough drug: Treatment of bone marrow growth syndrome!
Time of Update: 2020-10-07
September 16, 2020 // -- Gilead Sciences recently announced that the U.S. Food and Drug Administration (FDA) has granted magolimab Breakthrough Drug Qualification (BTD), the first anti-CD47 monoclonal antibody to treat newly diagnosed myeloid growth syndrome (MDS).
Junshi Bio announced its interim results for 2020, with research and development investment up 92% year-on-year!
Time of Update: 2020-09-28
press release, the company has made significant progress in product commercialization, clinical trials and pipeline expansion, with unaudited revenue of $575 million, up 86% year-on-year.
for New Allergies: Hematological Remission Rate Up to 92%
Time of Update: 2020-09-26
September 11, 2020 // -- Johnson and Johnson (JNJ)'s Janssen Pharmaceuticals recently announced that it has filed a Supplemental Biologics Licensing Application (SBLA) with the U.S. Food and Drug Administration (FDA) seeking approval for Darzalex
hydroxybutyrate magnesium potassium), reducing sodium intake by 92%!
Time of Update: 2020-07-28
The U.S. Food and Drug Administration () has approved an oral solution (sodium hydroxybutylate, potassium, magnesium, calcium) for the treatment of denarcing or excessive daytime drowsiness in patients with narcolepsy (narcolepsy) and older